CAR T cells with boosted BACH2 protein can fight cancer more effectively

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Active aldehydes drive T cell exhaustion in the tumor microenvironment, finds study

Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...
Medscape

Novel CAR T Cells Show Promise for Resistant T-Cell ALL

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
The New England Journal of Medicine

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
Healio

Rheumatologists view CAR T-cell therapy as ‘revolutionary,’ but cost, safety temper enthusiasm

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Targeted Oncology

Nivolumab Shows Marginal ORR Following CAR T Failure in MM, NHL

Treatment with nivolumab (Opdivo) had limited benefit in patients with multiple myeloma (MM) or non-Hodkin lymphoma (NHL) ...